Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RallybioFRA:33M0 -1.42%18 Market Cap is €75.57 Mil as of Jul. 26, 2026. GuruFocus rates FRA:33M0 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 1,422 Biotechnology companies, Rallybio ranks worse than 54.5% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rallybio's share price for the quarter that ended in Mar. 2026 was €0. Rallybio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 5.29 Mil. Therefore, Rallybio's market cap for the quarter that ended in Mar. 2026 was €0.00 Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rallybio's Enterprise Value for Today is €34.57 Mil.
Rallybio (FRA:33M0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rallybio Market Cap Related Terms
Rallybio Market Cap Historical Data
* Premium members only.
The historical data trend for Rallybio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rallybio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rallybio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rallybio's Market Cap distribution charts can be found below:
* The bar in red indicates where Rallybio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rallybio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rallybio (FRA:33M0) has a Market Cap of €75.57 Mil as of Jul. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rallybio and its competitors. According to the industry distribution chart, Rallybio ranks #775 out of 1422 companies in the Biotechnology industry, placing it in the top 54.5%.
Is Rallybio's Market Cap too high?
Rallybio's current Market Cap is €75.57 Mil. Based on the distribution chart, Rallybio ranks #775 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rallybio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rallybio's Market Cap compare to ?
According to the Biotechnology industry distribution chart, Rallybio ranks #775 out of 1422 companies for Market Cap. This places Rallybio in the lower half of its industry. The industry median Market Cap is 110.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 110.94, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rallybio and its competitors. For the Biotechnology industry, the median Market Cap is 110.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rallybio's current Market Cap is €75.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rallybio stock overvalued right now?
Rallybio (FRA:33M0) has a current Market Cap of €75.57 Mil. The current Market Cap is €75.57 Mil. Rallybio's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Rallybio (FRA:33M0), the current Market Cap is €75.57 Mil as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
18GF Score
Get the complete analysis for FRA:33M0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:33M0 has been successfully added to your 
